全球足底筋膜炎治療市場規模、份額和趨勢分析報告—產業概況和 2032 年預測

足底筋膜炎治療市場規模

• 2024 年全球足底筋膜炎治療市場規模為15.3 億美元 ，預計 到 2032 年將達到 24.9 億美元，預測期內 複合年增長率為 6.20%。
• 市場成長主要源自於足跟痛和足部疾病盛行率的上升，尤其是在老年人口、運動員以及肥胖或長期站立的人群中。這導致全球醫療機構對保守和先進的足底筋膜炎治療方案的需求不斷增長。
• 此外，消費者對非侵入性、經濟高效的療法（如矯正器、物理治療和衝擊波療法）的日益青睞，也加速了創新治療產品的普及化。這些因素的共同作用顯著提升了足底筋膜炎治療方案的普及率，從而推動了產業的整體成長軌跡。

足底筋膜炎治療市場分析

• 足底筋膜炎治療方案涵蓋非手術和手術幹預，用於治療足跟疼痛和發炎。由於其能夠有效恢復患者活動能力並減輕慢性足部不適，足底筋膜炎在骨科和運動醫學領域變得越來越重要。這些治療方法廣泛應用於各種人群，包括運動員、老年人和職業壓力人群。
• 足底筋膜炎治療需求的不斷增長，主要原因是全球足部和足跟疾病發病率的上升、人們對早期幹預的認識的提高，以及對物理治療、矯形鞋墊和體外震波療法 (ESWT) 等非侵入性解決方案的日益青睞
• 北美在足底筋膜炎治療市場佔據主導地位，2024 年其收入份額最大，為 41.6%，這得益於先進的醫療基礎設施、現代治療設備的早期採用，以及提供保守和先進治療的領先企業的強大影響力
• 預計亞太地區將成為預測期內足底筋膜炎治療市場成長最快的地區，複合年增長率為 7.8%，這得益於中國、印度和日本等國家老年人口的增長、醫療保健投資的增加以及足病護理服務的改善
• 矯正器在足底筋膜炎治療市場佔據主導地位，2024 年的市佔率為 43.2%，這得益於其療效可靠、價格實惠且普及。這些產品為患者提供非侵入性疼痛緩解，通常是醫療保健提供者開立的首選治療方案，進一步鞏固了其市場領導地位。

報告範圍和足底筋膜炎治療市場細分

足底筋膜炎治療市場趨勢

“透過數位治療和穿戴式裝置整合提高便利性”

• 全球足底筋膜炎治療市場的一個重要且加速發展的趨勢是數位療法與穿戴式健康技術的日益融合，這提高了治療的精準度、患者的依從性和日常使用的舒適度。這些進步使得足底筋膜炎的治療方案更加主動和個人化。
  • For instance, smart insoles equipped with pressure sensors and real-time gait analysis are being introduced, enabling patients and healthcare providers to monitor foot stress and adjust therapy protocols accordingly. Wearables such as the Walkasins system use biofeedback to assist with foot stability and reduce heel pressure, directly addressing plantar fascia strain
• Digital apps integrated with wearable devices provide users with guided stretching routines, progress tracking, and pain monitoring. Some systems even use AI to analyze walking patterns and provide predictive alerts for high-risk activities or flare-ups, allowing early intervention before pain escalates
• The seamless integration of wearable technology with telehealth platforms also enables remote physiotherapy and podiatric consultations, eliminating the need for frequent clinic visits and making treatment more accessible, especially for the elderly and mobility-challenged populations
• This trend toward more intelligent, data-driven, and patient-centered care is reshaping consumer expectations. Companies such as TheraWear and FitMyFoot are leveraging AI-powered customization and 3D-printing technology to offer orthotic insoles tailored to individual foot biomechanics, promoting better alignment and long-term relief
• The demand for wearable-integrated plantar fasciitis treatments is growing rapidly across both medical and consumer wellness sectors, as patients increasingly prioritize non-invasive, tech-enabled, and convenient recovery solutions

Plantar Fasciitis Treatment Market Dynamics

Driver

“Growing Need Due to Increasing Prevalence and Demand for Non-Invasive Therapies”

• The rising global prevalence of plantar fasciitis, particularly among aging populations, athletes, and individuals with obesity or sedentary lifestyles, is a significant driver fueling demand for advanced treatment solutions
  • For instance, in March 2024, MediTouch Digital Health announced the launch of an AI-powered foot care platform designed to track gait and recommend personalized orthotic and stretching regimens for plantar fasciitis sufferers. Innovations such as these are enhancing early intervention and accelerating recovery, thereby driving market growth
• As awareness of plantar fasciitis increases, patients and healthcare providers are prioritizing conservative, non-invasive treatment approaches such as orthotic insoles, physical therapy, and shockwave therapy before considering surgical alternatives
• Furthermore, the surge in remote healthcare solutions and wearable technologies is making it easier for patients to manage plantar fasciitis at home, leading to improved compliance and treatment outcomes
• The demand for convenient, low-risk, and cost-effective solutions is encouraging product innovations that blend digital tracking, biomechanical support, and therapeutic relief. With insurance providers increasingly covering non-surgical options, accessibility to effective plantar fasciitis treatments is growing across diverse income groups

Restraint/Challenge

“Limited Long-Term Effectiveness and Cost Barriers in Advanced Therapies”

• One of the major challenges in the plantar fasciitis treatment market is the limited long-term effectiveness of certain conservative treatments, particularly when used in isolation. Recurrence rates remain high without sustained intervention or lifestyle modification, often leading to patient dissatisfaction
  • For instance, while orthotic insoles and night splints offer short-term relief, they may not address underlying biomechanical issues or chronic inflammation, which can cause persistent symptoms despite regular use
• Moreover, advanced treatment options such as extracorporeal shock wave therapy (ESWT), platelet-rich plasma (PRP) injections, and laser therapy, though promising, are often expensive and not always covered by standard insurance plans. This restricts accessibility, especially in cost-sensitive markets or among uninsured patients
• Concerns about out-of-pocket expenses and the need for multiple therapy sessions discourage some individuals from pursuing or continuing with these advanced treatments, hindering broader market adoption
• To overcome these challenges, stakeholders must focus on comprehensive care models that combine physical therapy, supportive footwear, and education, while manufacturers work towards making premium treatments more affordable and accessible to a wider population

Plantar Fasciitis Treatment Market Scope

The plantar fasciitis treatment market is segmented on the basis of treatment type, end-user, and indication.

• By Treatment Type

On the basis of treatment type, the plantar fasciitis treatment market is segmented into pharmacological treatment, medication therapy, orthotic devices, shockwave therapy, surgery, and other treatment types. The orthotic devices segment dominates the largest market revenue share of 43.2% in 2024, driven by its non-invasive nature, cost-effectiveness, and wide availability through retail and e-commerce platforms. These devices provide mechanical support and pain relief, making them a first-line choice for early-stage plantar fasciitis and preventive care. The segment continues to grow due to rising awareness about foot health and the increasing use of custom orthotics.

The shockwave therapy segment is anticipated to witness the fastest CAGR of 8.9% from 2025 to 2032, owing to its growing use as an effective non-surgical treatment for chronic cases. Its ability to stimulate healing and reduce inflammation without downtime is gaining traction among healthcare providers and patients seeking alternatives to surgery.

• By End-User

On the basis of end-user, the plantar fasciitis treatment market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market revenue share of 42.1% in 2024, attributed to the availability of comprehensive treatment options under one roof, including diagnostics, imaging, and advanced therapeutic modalities. Hospitals also benefit from better reimbursement infrastructure, particularly in developed markets.

The clinics segment is expected to witness the fastest CAGR of 7.6% from 2025 to 2032, driven by the rise of specialty podiatric and physiotherapy clinics. These clinics offer targeted treatment in outpatient settings with shorter wait times and personalized care, increasingly preferred by patients managing mild to moderate symptoms.

• By Indication

On the basis of indication, the plantar fasciitis treatment market is segmented into mild, moderate, and severe. The moderate segment held the largest market share of 46.3% in 2024, as a significant portion of patients fall into this category and seek intervention after self-care fails. Moderate cases often require structured treatment plans involving multiple modalities, such as orthotics, physiotherapy, and pharmacologic support.

The severe segment is projected to witness the fastest CAGR of 9.2% from 2025 to 2032, due to the increasing availability of advanced therapies such as shockwave, PRP injections, and minimally invasive surgical options. Greater access to specialty care and improved diagnostic tools are enabling earlier detection and better outcomes in complex cases.

Plantar Fasciitis Treatment Market Regional Analysis

• North America dominates the plantar fasciitis treatment market with the largest revenue share of 41.6% in 2024, driven by a rising prevalence of obesity, aging population, and increasing participation in sports-related activities that elevate the risk of heel pain and plantar injuries
• Consumers in the region increasingly seek both pharmacologic and non-invasive treatment solutions, such as orthotic devices and physical therapy, to manage chronic heel pain and maintain mobility
• This growing demand is further supported by high healthcare expenditure, access to advanced podiatric care, and the presence of key market players focusing on innovative treatment options, positioning North America as a leader in addressing plantar fasciitis through both clinical and home-based therapies

U.S. Plantar Fasciitis Treatment Market Insight

2024年，美國足底筋膜炎治療市場佔據北美地區最高收入份額，達79.5%，這得益於老齡人口增長、高肥胖率以及支持早期診斷和治療的強大醫療基礎設施。運動員和專業人士對足底筋膜炎的認識不斷提高，加上物理治療和矯正器保險覆蓋範圍的擴大，推動了該治療的普及。此外，美國製藥和醫療器材公司也越來越重視開發更便利的非侵入性治療方案。

歐洲足底筋膜炎治療市場洞察

預計歐洲足底筋膜炎治療市場在預測期內將以6.3%的複合年增長率增長，這得益於公共衛生舉措的不斷推進、足部疾病病例的增加以及人們對慢性足跟痛早期幹預意識的不斷提升。歐洲各國的骨科諮詢和足病照護需求正在上升，尤其是在久坐不動的生活方式和人口老化加劇慢性肌肉骨骼疾病的情況下。

英國足底筋膜炎治療市場洞察

英國足底筋膜炎治療市場預計在2025年至2032年間的複合年增長率將達到6.8%，這得益於人們對預防性醫療保健的日益重視，以及物理治療和客製化矯形解決方案的興起。醫療保健支出的不斷增長、強大的足病診所網絡是關鍵推動因素，同時，老齡化人口也日益尋求緩解慢性足部疼痛。

德國足底筋膜炎治療市場洞察

預計德國足底筋膜炎治療市場在預測期內將以 6.5% 的複合年增長率成長，這得益於專科醫療服務的普及、骨科疾病盛行率的上升以及政府對醫療基礎設施的大力投資。德國對早期介入的重視，加上衝擊波療法和穿戴式矯正器等醫療設備的創新，正在支撐市場擴張。

亞太地區足底筋膜炎治療市場洞察

受都市化進程加速、可支配所得增加以及新興經濟體醫療保健可近性改善的影響，亞太地區足底筋膜炎治療市場可望在2025年至2032年間以7.8%的複合年增長率保持最快成長。中國、印度和東南亞各國政府為提高肌肉骨骼健康意識所採取的舉措，正在推動保守治療和手術治療的需求。門診復健中心的成長以及矯正器價格的可負擔性，進一步支撐了該地區的成長。

日本足底筋膜炎治療市場洞察

日本足底筋膜炎治療市場預計將以7.2%的複合年增長率成長，這得益於日本高比例的老年人口以及國家對行動能力和老齡化相關問題的高度重視。日本消費者青睞微創療法和家用矯正器。此外，治療設備和復健項目的技術創新也推動了該市場的持續成長。

中國足底筋膜炎治療市場洞察

2024年，中國足底筋膜炎治療市場佔亞太地區最大收入份額，達42.6%。這得益於足部護理產品普及率的提高、私人醫療機構的快速擴張以及人們對早期治療的認識的提高。政府對骨科護理的大力投入、運動產業的蓬勃發展以及糖尿病患者的不斷增長，也是推動城市和半城市地區足底筋膜炎治療需求成長的關鍵因素。

印度足底筋膜炎治療市場洞察

預計2025年至2032年，印度足底筋膜炎治療市場的複合年增長率將達到9.3%，成為亞洲成長最快的市場之一。推動這一增長的因素包括：肥胖率上升、生活方式相關疾病盛行率上升，以及越來越多的中產階級尋求慢性足跟痛的早期治療。

城市化和久坐不動的工作模式導致肌肉骨骼和骨科問題激增，尤其是在專業人士和老齡化人口中。此外，大城市足病服務的普及以及物理治療和骨科診所的增多，也提高了病患獲得醫療服務的機會。

足底筋膜炎治療市佔率

足底筋膜炎治療產業主要由知名公司主導，包括：

• 拜耳公司（德國）
• Superfeet（美國）
• 鮑爾芬德（德國）
• Shapecrunch（印度）
• 3M（美國）
• OrthoBethesda（美國）
• 藥劑師產品（美國）
• Ellis & Badenhausen 骨科，PSC（美國）
• SYNXSOLE PTY LTD.（澳洲）
• REVANCE（美國）
• Scholl's Wellness Co.（美國）
• 新百倫（美國）
• Implus Footcare LLC（美國）
• Foot Levelers, Inc.（美國）
• 索倫製造有限公司（中國）
• Vionic Group LLC（美國）
• Powerstep（美國）

全球足底筋膜炎治療市場的最新發展

• 2025年4月， 《自我》雜誌發表的一項研究強調了體外脈衝激活技術 (EPAT) 和富血小板血漿注射等新療法在治療足底筋膜炎方面的有效性。這些療法在尋求更快康復方案的活躍人士中越來越受歡迎。
• 2023年7月，North Star Vascular & Interventional 推出了一項創新的非侵入性足底筋膜炎治療技術—足底筋膜炎栓塞術。該手術為尋求非侵入性治療的患者提供了一個非常有效的解決方案。
• 2022年9月，Aetrex Inc. 推出了 Foot.com 數據門戶，這是一個專門的平台，旨在幫助鞋類製造商生產更舒適的鞋款。該計劃旨在提高足底筋膜炎治療中使用的矯正器的有效性。
• 2022年6月，Atlecko推出了一款12件式足底筋膜炎襪套裝，以幫助緩解足底筋膜炎疼痛。該產品為尋求緩解足跟痛的患者提供了一種非侵入性治療方案。
• 2022年10月，Patient Square Capital以12.5億美元收購了Hanger Inc.。此次收購預計將加速Hanger的成長目標，尤其是在基於價值的護理創新領域，包括有助於治療足底筋膜炎的踝足矯正器(AFO)等醫療器材。

SKU-46328